These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35840661)

  • 1. Tutorial: design and execution of CRISPR in vivo screens.
    Braun CJ; Adames AC; Saur D; Rad R
    Nat Protoc; 2022 Sep; 17(9):1903-1925. PubMed ID: 35840661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting Molecular Phenotypes Through FACS-Based Pooled CRISPR Screens.
    Genolet O; Ravid Lustig L; Schulz EG
    Methods Mol Biol; 2022; 2520():1-24. PubMed ID: 35218528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Making better CRISPR libraries.
    Zhu S; Wei W
    Elife; 2016 Nov; 5():. PubMed ID: 27809196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets.
    Noorani I; Bradley A; de la Rosa J
    Genome Biol; 2020 Aug; 21(1):204. PubMed ID: 32811551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic screens: Combining CRISPR perturbations and RNA-seq.
    Burgess DJ
    Nat Rev Genet; 2017 Jan; 18(2):67. PubMed ID: 28096529
    [No Abstract]   [Full Text] [Related]  

  • 6. Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects.
    Dempster JM; Boyle I; Vazquez F; Root DE; Boehm JS; Hahn WC; Tsherniak A; McFarland JM
    Genome Biol; 2021 Dec; 22(1):343. PubMed ID: 34930405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled Genome-Scale CRISPR Screens in Single Cells.
    Schraivogel D; Steinmetz LM; Parts L
    Annu Rev Genet; 2023 Nov; 57():223-244. PubMed ID: 37562410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Massively Parallel CRISPR-Based Genetic Perturbation Screening at Single-Cell Resolution.
    Cheng J; Lin G; Wang T; Wang Y; Guo W; Liao J; Yang P; Chen J; Shao X; Lu X; Zhu L; Wang Y; Fan X
    Adv Sci (Weinh); 2023 Feb; 10(4):e2204484. PubMed ID: 36504444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR activation screens: navigating technologies and applications.
    Clark T; Waller MA; Loo L; Moreno CL; Denes CE; Neely GG
    Trends Biotechnol; 2024 Mar; ():. PubMed ID: 38493051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled CRISPR screening of high-content cellular phenotypes using ghost cytometry.
    Tsubouchi A; An Y; Kawamura Y; Yanagihashi Y; Nakayama H; Murata Y; Teranishi K; Ishiguro S; Aburatani H; Yachie N; Ota S
    Cell Rep Methods; 2024 Mar; 4(3):100737. PubMed ID: 38531306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promise of genetic screens in human
    Beirute-Herrera J; López-Amo Calvo B; Edenhofer F; Esk C
    Biol Chem; 2024 Jan; 405(1):13-24. PubMed ID: 37697643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer.
    Falcomatà C; Bärthel S; Schneider G; Rad R; Schmidt-Supprian M; Saur D
    Cancer Discov; 2023 Feb; 13(2):278-297. PubMed ID: 36622087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.
    Akram F; Haq IU; Sahreen S; Nasir N; Naseem W; Imitaz M; Aqeel A
    Technol Cancer Res Treat; 2022; 21():15330338221132078. PubMed ID: 36254536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-scale pan-cancer interrogation of lncRNA dependencies using CasRx.
    Montero JJ; Trozzo R; Sugden M; Öllinger R; Belka A; Zhigalova E; Waetzig P; Engleitner T; Schmidt-Supprian M; Saur D; Rad R
    Nat Methods; 2024 Apr; 21(4):584-596. PubMed ID: 38409225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The double-edge sword of CRISPR application for
    Thomsen MK
    Oncotarget; 2023 Nov; 14():919-920. PubMed ID: 38010820
    [No Abstract]   [Full Text] [Related]  

  • 16. CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy.
    Ding S; Liu J; Han X; Tang M
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancements in CRISPR screens for the development of cancer immunotherapy strategies.
    Li YR; Lyu Z; Tian Y; Fang Y; Zhu Y; Chen Y; Yang L
    Mol Ther Oncolytics; 2023 Dec; 31():100733. PubMed ID: 37876793
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Fischer A; Lersch R; de Andrade Krätzig N; Strong A; Friedrich MJ; Weber J; Engleitner T; Öllinger R; Yen HY; Kohlhofer U; Gonzalez-Menendez I; Sailer D; Kogan L; Lahnalampi M; Laukkanen S; Kaltenbacher T; Klement C; Rezaei M; Ammon T; Montero JJ; Schneider G; Mayerle J; Heikenwälder M; Schmidt-Supprian M; Quintanilla-Martinez L; Steiger K; Liu P; Cadiñanos J; Vassiliou GS; Saur D; Lohi O; Heinäniemi M; Conte N; Bradley A; Rad L; Rad R
    Cell Genom; 2023 Mar; 3(3):100276. PubMed ID: 36950387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A CRISPR Path to Finding Vulnerabilities and Solving Drug Resistance: Targeting the Diverse Cancer Landscape and Its Ecosystem.
    McLean B; Istadi A; Clack T; Vankan M; Schramek D; Neely GG; Pajic M
    Adv Genet (Hoboken); 2022 Dec; 3(4):2200014. PubMed ID: 36911295
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.